Drugs for Neglected Diseases initiative (DNDi) Revenue and Competitors
Estimated Revenue & Valuation
- Drugs for Neglected Diseases initiative (DNDi)'s estimated annual revenue is currently $58.3M per year.
- Drugs for Neglected Diseases initiative (DNDi)'s estimated revenue per employee is $127,500
Employee Data
- Drugs for Neglected Diseases initiative (DNDi) has 457 Employees.
- Drugs for Neglected Diseases initiative (DNDi) grew their employee count by 10% last year.
Drugs for Neglected Diseases initiative (DNDi)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head, Media and Content | Reveal Email/Phone |
2 | Head the Filarial Program | Reveal Email/Phone |
3 | Head External Relations | Reveal Email/Phone |
4 | Head Accounting (Mat. Leave Contract) | Reveal Email/Phone |
5 | Head Accounting | Reveal Email/Phone |
6 | Finance Officer | Reveal Email/Phone |
7 | Head Drug Discovery | Reveal Email/Phone |
8 | Consultant Officer | Reveal Email/Phone |
9 | Head Cutaneous Leishmaniasis Programme | Reveal Email/Phone |
10 | Finance Officer FP&A | Reveal Email/Phone |
Drugs for Neglected Diseases initiative (DNDi) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13M | 127 | 43% | N/A | N/A |
#2 | $11.2M | 110 | 62% | N/A | N/A |
#3 | $27.3M | 243 | 10% | N/A | N/A |
#4 | $26M | 237 | 25% | $11M | N/A |
#5 | $3.3M | 41 | -11% | N/A | N/A |
#6 | $11.6M | 114 | 24% | N/A | N/A |
#7 | $1.6M | 22 | 5% | N/A | N/A |
#8 | $34.9M | 548 | 18% | N/A | N/A |
#9 | $50.2M | 394 | -5% | N/A | N/A |
#10 | $13.6M | 243 | -10% | N/A | N/A |
What Is Drugs for Neglected Diseases initiative (DNDi)?
The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patient-needs driven, not-for-profit research and development (R&D) organization that develops safe, effective, and affordable treatments for the millions of people across the world affected by neglected diseases, notably human African trypanosomiasis (sleeping sickness), leishmaniasis, Chagas disease, filarial infections, paediatric HIV, mycetoma, and hepatitis C. Launched in 2016 by the World Health Organization (WHO) and DNDi, the Global Antibiotic Research & Development Partnership (GARDP) aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists, while endeavouring to ensure sustainable access. GARDP is currently operating within DNDi, which provides its governance.
keywords:N/A
N/A
Total Funding
457
Number of Employees
$58.3M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Drugs for Neglected Diseases initiative (DNDi) News
Kieny, a virologist and vaccinologist, is chair of the board of the Drugs for Neglected Diseases Initiative (DNDi) and director of research at...
BenevolentAI and Drugs for Neglected Disease initiative (DNDi) have commenced a joint AI research project to address dengue.
The Drugs for Neglected Diseases Initiative (DNDi) has asked Pfizer for supplies of its antiviral drug Paxlovid to use in the ANTICOV...
Other Companies in Geneva
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $123.1M | 469 | 6% | N/A |
#2 | $123.1M | 469 | 6% | N/A |
#3 | $168.4M | 499 | 26% | N/A |
#4 | $101.2M | 506 | 4% | N/A |
#5 | $93.5M | 516 | 4% | N/A |